Skip to content
lifestyle.cleanweb.co
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Opus Genetics, Inc.
Opus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate Update
August 6, 2026
Opus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 for LCA5-Associated Inherited Retinal Disease
August 3, 2026
Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease Experts
June 2, 2026
Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 28, 2026
Opus Genetics to Present at the 2026 Jefferies Global Healthcare Conference
May 27, 2026
Opus Genetics to Present at the RBC Capital Markets 2026 Global Healthcare Conference
May 13, 2026
Opus Genetics Announces Financial Results for First Quarter 2026 and Provides Corporate Update
May 12, 2026
Opus Genetics Presents Clinical and Preclinical Data at ARVO 2026 Demonstrating Continued Pipeline Advancement in Inherited Retinal Diseases
May 7, 2026
Opus Genetics Completes Enrollment in Cohort 1 of Phase 1/2 OPGx-BEST1 Gene Therapy Study
May 7, 2026
Opus Genetics Announces FDA Acceptance of OPGx-LCA5 into Rare Disease Evidence Principles (RDEP) Program
May 5, 2026
1
2
Next Page
→